ArticleScientific reports2026
Metabolic profiles of amino acids in patients with crohn's disease-associated perianal fistulas and cryptoglandular anal fistulas.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Crohn's disease-associated perianal fistulas (PFCD) and Cryptoglandular anal fistulas (CAF) are two types of fistulas with similar clinical manifestations but distinct etiologies and therapeutic strategies. This study aims to investigate serum amino acid metabolic profiles in patients with CAF and PFCD based on UPLC-MS/MS. Serum samples were enrolled from newly diagnosed and treatment-naïve 36 patients with active PFCD and 36 patients with CAF as controls. Clinical characteristics were systematically documented. Serum concentrations of 25 amino acids were quantitatively determined using UPLC-MS/MS with isotopically labeled internal standards. Multivariate statistical analyses were employed to discriminate metabolic profiles between groups. Pathway enrichment analysis of differential amino acids was performed using Metabo Analyst 5.0. The PFCD cohort exhibited significantly lower total serum amino acid concentrations compared to CAF group, with 13 differentially expressed amino acids identified. Multivariate analyses revealed a significant separation trend between the two groups, eight amino acids were prioritized as candidate diagnostic biomarkers. Metabolic pathway enrichment analysis demonstrated that five pathways showed significant associations with metabolic disparities between the two groups. The proposed biomarker panel may assist in differentiating PFCD from CAF and guide individualized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.